Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGALS8 | O00214 | 3/20 | 0.54 |
| ▸ | LGALS3 | P17931 | 3/20 | 0.54 |
| ▸ | LGALS4 | P56470 | 3/20 | 0.54 |
| ▸ | GJB2 | P29033 | 5/20 | 0.51 |
| ▸ | ENGASE | Q8NFI3 | 1/20 | 0.44 |
| ▸ | TLR4 | O00206 | 1/20 | 0.43 |
| ▸ | AMY2A | P04746 | 3/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9804026 | 1.00 | LGALS8 (0.54) | LGALS8LGALS3LGALS4GJB2ENGASE | |
| SCHEMBL4990033 | 0.95 | LGALS8 (0.50) | LGALS8LGALS3LGALS4GJB2ENGASE | |
| SCHEMBL8439367 | 0.95 | LGALS8 (0.50) | LGALS8LGALS3LGALS4GJB2ENGASE | |
| SCHEMBL17688998 | 0.93 | LGALS8 (0.52) | LGALS8LGALS3LGALS4GJB2AMY2A | |
| SCHEMBL17688996 | 0.91 | GJB2 (0.50) | LGALS8LGALS3LGALS4GJB2ENGASE | |
| SCHEMBL15295476 | 0.88 | LGALS8 (0.54) | LGALS8LGALS3LGALS4GJB2ENGASE | |
| SCHEMBL8491597 | 0.88 | LGALS3 (0.52) | LGALS8LGALS3LGALS4ENGASEAMY2A | |
| SCHEMBL18199629 | 0.87 | TLR4 (0.51) | LGALS8LGALS3LGALS4GJB2TLR4 | |
| SCHEMBL10016614 | 0.87 | TLR4 (0.51) | LGALS8LGALS3LGALS4GJB2TLR4 | |
| SCHEMBL9999695 | 0.87 | TLR4 (0.51) | LGALS8LGALS3LGALS4GJB2TLR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260041775-A1 | COMPOSITIONS FOR DRUG ADMINISTRATION | AEGIS THERAPEUTICS, LLC (US) | 2026-02-12 | — | — | US | disclosed |
| US-11173209-B2 | Compositions for drug administration | AEGIS THERAPEUTICS, LLC (US) | 2021-11-16 | — | — | US | disclosed |
| US-20210121573-A1 | ABSORPTION ENHANCERS FOR DRUG ADMINISTRATION | AEGIS THERAPEUTICS, LLC | 2021-04-29 | — | — | US | disclosed |
| US-20200138956-A1 | COMPOSITIONS FOR DRUG ADMINISTRATION | AEGIS THERAPEUTICS, LLC | 2020-05-07 | — | — | US | disclosed |
| US-10576156-B2 | Compositions for drug administration | AEGIS THERAPEUTICS, LLC (US) | 2020-03-03 | — | — | US | disclosed |
| US-20190209689-A1 | ABSORPTION ENHANCERS FOR DRUG ADMINISTRATION | AEGIS THERAPEUTICS LLC (US) | 2019-07-11 | — | — | US | disclosed |
| US-10265402-B2 | Absorption enhancers for drug administration | AEGIS THERAPEUTICS, LLC (US) | 2019-04-23 | — | — | US | disclosed |
| US-20180325994-A1 | ANTI-BACTERIAL COMPOSITIONS FOR DRUG ADMINISTRATION | AEGIS THERAPEUTICS, LLC | 2018-11-15 | — | — | US | disclosed |
| US-20180221489-A1 | ABSORPTION ENHANCERS FOR DRUG ADMINISTRATION | AEGIS THERAPEUTICS, LLC | 2018-08-09 | — | — | US | disclosed |
| US-20180169247-A1 | COMPOSITIONS FOR DRUG ADMINISTRATION | AEGIS THERAPEUTICS, LLC | 2018-06-21 | — | — | US | disclosed |
| WO-2006025882-A2 | ABSORPTION ENHANCERS FOR DRUG ADMINISTRATION | THE UAB RESEARCH FOUNDATION (US) | 2006-03-09 | — | — | WO | disclosed |
| US-20060046962-A1 | Absorption enhancers for drug administration | AEGIS THERAPEUTICS LLC (US) | 2006-03-02 | — | — | US | disclosed |
| US-20060045868-A1 | Absorption enhancers for drug administration | AEGIS THERAPEUTICS LLC | 2006-03-02 | — | — | US | disclosed |
| US-20060046969-A1 | Antibacterial compositions for drug administration | AEGIS THERAPEUTICS LLC (US) | 2006-03-02 | — | — | US | disclosed |
| US-20060045869-A1 | Absorption enhancers for drug administration | AEGIS THERAPEUTICS LLC | 2006-03-02 | — | — | US | disclosed |
| EP-0254771-B2 | Detection of microbes in a sample | EDBERG STEPHEN C (US) | 2000-02-02 | — | — | EP | disclosed |
| US-5661130-A | NONTOXIC, NONIONIC ALKYL GLYCOSIDE HAVING A HYDROPHOBIC ALKYL JOINED BY A LINKAGE TO A HYDROPHILIC SACCHARIDE | THE UAB RESEARCH FOUNDATION (US) | 1997-08-26 | — | — | US | disclosed |
| WO-1995000151-A1 | ABSORPTION ENHANCERS FOR DRUG ADMINISTRATION | UAB RESEARCH FOUNDATION (US) | 1995-01-05 | — | — | WO | disclosed |
| US-4925789-A | COLORIMETRIC ANALYSIS | EDBERG STEPHEN C (US) | 1990-05-15 | — | — | US | disclosed |
| EP-0254771-A2 | Detection of microbes in a sample | Edberg, Stephen C. (US) | 1988-02-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11173209-B2 | Compositions for drug administration | SLC10A1, ABCB11, CSGALNACT1 | LGALS8 34/4885LGALS3 28/4885LGALS4 47/4885 |
| US-20180169247-A1 | COMPOSITIONS FOR DRUG ADMINISTRATION | SLC10A1, ABCB11, CSGALNACT1 | LGALS8 34/4885LGALS3 28/4885LGALS4 47/4885 |
| US-20260041775-A1 | COMPOSITIONS FOR DRUG ADMINISTRATION | SLC2A8, SLC5A2, SLC2A4 | LGALS8 724/4885LGALS3 1331/4885LGALS4 752/4885 |
| US-20200138956-A1 | COMPOSITIONS FOR DRUG ADMINISTRATION | SLC10A1, ABCB11, CSGALNACT1 | LGALS8 34/4885LGALS3 28/4885LGALS4 47/4885 |
| US-10576156-B2 | Compositions for drug administration | SLC10A1, ABCB11, CSGALNACT1 | LGALS8 34/4885LGALS3 28/4885LGALS4 47/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.